[Studies of the clinical use of cycloplatin--a new derivative of cisplatin].
The preliminary results of Cycloplatin in non small cell lung cancer were presented. Cycloplatin is a new derivative of Cisplatin but less nephrotoxic. Its. referring preparation is Carboplatin 14% remissions were found in the cases of inoperable non small cell lung cancer and 12% remissions in advanced ovarian cancer. 84% of patients suffered from vomiting what was the most common reported side-effect.
Koralewski
P
P
Kliniki Chemioterapii Centrum Onkologii Instytutu im. Marii Skłodowkiej-Curie, Oddział, Krakowie.
Pawlicki
M
M
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000633:toxicity; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D013921:Thrombocytopenia / Q000139:chemically induced*; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C055928:cycloplatam
Badania nad zastosowaniem klinicznym cycloplatyny--nowej pochodnej cisplatyny.